In this cohort study of 506 544 unrelated individuals, incidentally identified moderate-risk RET variants were associated with substantially lower medullary thyroid cancer risk compared with clinically ascertained cases with suspected multiple endocrine neoplasia type 2 (2.8%-19.0% vs 98.2%). The gene discussed is RET; the disease is multiple endocrine neoplasia type 2.